Mountain View
biomedical and healthCAre Data Discovery Index Ecosystem
help Advanced Search
Title: Transcription profiling of human lymphoblastoid cell lines - HapMap cell lines CEU, JPT/CHB and YRI treated anti-cancer agents: 5-fluorouracil (5FU), methotrexate (MTX), simvastatin, SAHA, 6-mercaptopurine (6MP), rapamycin, and bortezomib      
dateReleased:
06-19-2008
description:
Lymphoblastoid cell lines (LCLs), originally collected as renewable sources of DNA, are now being used as a model system to study genotype-phenotype relationships in human cells. These cell lines have been used to search for genetic variants that are associated with drug response as well as with more basic cellular traits such as RNA levels. In setting out to extend such studies by searching for genetic variants contributing to drug response, we observed that phenotypes in LCLs were, in our lab and others, significantly affected by experimental confounders (i.e. in vitro growth rate, metabolic state, and relative levels of the Epstein-Barr virus used to transform the cells). As we did not find any SNPs associated with genome-wide significance to drug response, we evaluated whether incorporating RNA expression levels (and eQTLs) in the analysis could increase power to detect such effects. As previously shown, cis-acting eQTLs were detectable for a sizeable fraction of RNAs and baseline levels of many RNAs predicted response to several drugs. However, we found only limited evidence that SNPs influenced drug response through their effect on expression of RNA. Efforts to use LCLs to map genes underlying cellular traits will require great care to control experimental confounders, unbiased methods for integrating and interpreting such multi-dimensional data, and much larger sample sizes than have been applied to date. Experiment Overall Design: We studied 269 cell lines densely genotyped by the International HapMap Project [31]. Cell lines were cultured and characterized at baseline for a variety of cellular phenotypes including growth rate, ATP levels, mitochondrial DNA copy number, EBV copy number, and measures of B-cell relevant cell surface receptors and cytokine levels. Each cell line was exposed in 384-well plates to a range of doses for each of seven drugs selected based on their divergent mechanisms of action and importance in clinical use for treatment of B-cell diseases, focusing on anti-cancer agents: 5-fluorouracil (5FU), methotrexate (MTX), simvastatin, SAHA, 6-mercaptopurine (6MP), rapamycin, and bortezomib. Drug response was measured using Celltiter Glo, an ATP-activated intracellular luminescent marker that, when compared to mock-treated control wells, can represent relative levels of cellular viability and metabolic activity. RNA was collected at baseline and RNA transcript levels were measured genome-wide on the Affymetrix platform. Baseline characterization and plating for drug response experiments was performed using batches of 90 cell lines from each HapMap analysis panel (CEU, JPT / CHB, and YRI) on each of three experiment days. The order of cell lines within each panel was randomized to avoid inducing artificial intra-familial correlation. Each drug was tested at a range of doses around the expected IC50 as reported for the drug by the NCI DTP; each dose of drug was tested in two wells per plate and on two separate plates. These replicate measurements for each cell line allowed assessment of intra-experimental variation. To evaluate day-to-day (i.e. inter-experimental) variation in all traits, a subset of 90 cell lines (30 from each of the three HapMap panels) was grown from a fresh aliquot and the entire experiment was repeated. To evaluate the effect of technical error on measured RNA levels, a set of 22 RNAs previously expression profiled (using Illumina HumanChip) at Wellcome Trust Sanger Institute (WTSI) (generously provided by Emmanouil T. Dermatsakis) was included in expression profiling at the Broad on Affymetrix arrays. Data can be downloaded from the Broad Institute web site: (). Please see Materials and Methods for details of QC, normalization, etc.
privacy:
not applicable
aggregation:
instance of dataset
ID:
E-GEOD-11582
refinement:
raw
alternateIdentifiers:
11582
dateSubmitted:
05-28-2008
keywords:
functional genomics
dateModified:
06-10-2011
creators:
Roman Yelensky
availability:
available
types:
gene expression
name:
unknown experiment type
ID:
A-AFFY-33
name:
Affymetrix GeneChip Human Genome HG-U133A [HG-U133A]
accessURL: https://www.ebi.ac.uk/arrayexpress/files/E-GEOD-11582/E-GEOD-11582.raw.1.zip
storedIn:
ArrayExpress
qualifier:
gzip compressed
format:
TXT
accessType:
download
authentication:
none
authorization:
none
accessURL: https://www.ebi.ac.uk/arrayexpress/files/E-GEOD-11582/E-GEOD-11582.processed.1.zip
storedIn:
ArrayExpress
qualifier:
gzip compressed
format:
TXT
accessType:
download
authentication:
none
authorization:
none
accessURL: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE11582
storedIn:
Gene Expression Omnibus
qualifier:
not compressed
format:
HTML
accessType:
landing page
primary:
true
authentication:
none
authorization:
none
abbreviation:
EBI
homePage: http://www.ebi.ac.uk/
ID:
SCR:004727
name:
European Bioinformatics Institute
homePage: https://www.ebi.ac.uk/arrayexpress/
ID:
SCR:002964
name:
ArrayExpress

Feedback?

If you are having problems using our tools, or if you would just like to send us some feedback, please post your questions on GitHub.